Fibroblasts Promote Resistance to KRAS Silencing in Colorectal Cancer Cells

Susana Mendonça Oliveira1,2,3,4, Patrícia Dias Carvalho1,2,5, André Serra-Roma1,2

  • 1i3S-Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Rua Alfredo Allen 208, 4200-135 Porto, Portugal.

Cancers
|July 27, 2024
PubMed

Insights

Cancer-associated fibroblasts (CAFs) can drive resistance to KRAS-targeted therapy in colorectal cancer (CRC). CAF secretomes restore cancer stem cell markers and promote tumor-promoting pathways, suggesting external factors contribute to treatment failure.

Area of Science:

  • Oncology
  • Cancer Biology
  • Molecular Targeted Therapy

Background:

  • Colorectal cancer (CRC) exhibits limited response to KRAS-targeted therapies.
  • Mechanisms underlying resistance to KRAS inhibition in CRC are not fully understood.

Purpose of the Study:

  • To investigate the role of cancer-associated fibroblasts (CAFs) secretome in mediating resistance to KRAS silencing in CRC.
  • To explore how CAF-secreted factors influence cancer stem cell properties and signaling pathways in KRAS-silenced CRC cells.

Main Methods:

  • CRC cell lines (HCT15, HCT116, SW480) were cultured in normal or CAF-conditioned media.
  • Flow cytometry analyzed stem cell marker expression (CD24, CD49f, CD104).
  • Sphere formation assays assessed stem cell potential.
  • RNA sequencing (RNAseq) analyzed gene expression in KRAS-silenced cells treated with CAF-conditioned media.

Main Results:

  • KRAS silencing reduced stem cell marker expression and sphere-forming efficiency.
  • CAF-secreted factors reversed these effects, restoring stem cell markers and increasing stemness.
  • RNAseq revealed CAF factors up-regulated pro-tumorigenic pathways (KRAS, TGFβ, NOTCH, WNT, MYC, EMT) in KRAS-silenced cells.

Conclusions:

  • Resistance to KRAS-targeted inhibition in CRC may involve both cell-intrinsic factors and external signals from the tumor microenvironment, specifically CAF secretomes.
  • Fibroblast-secreted factors can promote stemness and activate oncogenic pathways, contributing to therapeutic resistance.

Related Concept Videos

Introduction to Fibroblasts01:09

Introduction to Fibroblasts

Rudolph Virchow discovered spindle-shaped cells called fibroblasts in 1858. Inactive fibroblasts, called fibrocytes, become activated by various stimuli, such as growth factors and inflammatory cytokines. Activated fibroblasts play a crucial role in wound healing, inflammation, formation of new blood vessels, and cancer progression. Uncontrolled activation of fibroblasts results in fibrosis, the excess deposition of fibrous tissue, which can lead to scarring and affect normal organs. This...
3.1K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
6.2K